SIDE-BY-SIDE EVIDENCE

Compare evidence.
Keep the context.

Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.

Choose profiles

SIDE-BY-SIDE EVIDENCE VIEW

Compare selected profiles

Evidence comparison · not a treatment ranking

Evidence boundaries, not cross-trial treatment outcomes
Molecule	Letrozole	Anastrozole	Exemestane
Research Topic	Clinical / Endocrine Pharmacology	Clinical / Endocrine Pharmacology	Clinical / Endocrine Pharmacology
Pharmacology	Aromatase inhibitor medicine	Nonsteroidal aromatase inhibitor medicine	Steroidal aromatase inhibitor medicine
PrimeCore Class	Class AApproved in a bounded context	Class AApproved in a bounded context	Class AApproved in a bounded context
Evidence Grade	Grade AStrong regulatory + clinical evidence	Grade AStrong regulatory + clinical evidence	Grade AStrong regulatory + clinical evidence
Evidence boundary	Letrozole is classified here as Aromatase inhibitor medicine. Randomised oncology evidence and prescription labels apply to defined breast-cancer populations and products. FDA-authorised prescription products exist for defined breast-cancer indications; WADA prohibits aromatase inhibitors at all times. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions.	Anastrozole is classified here as Nonsteroidal aromatase inhibitor medicine. Randomised oncology evidence supports defined breast-cancer contexts, not bodybuilding or routine adjunct use. FDA-authorised prescription products exist for defined breast-cancer indications; WADA prohibits aromatase inhibitors at all times. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions.	Exemestane is classified here as Steroidal aromatase inhibitor medicine. Clinical evidence and labels apply to defined postmenopausal breast-cancer settings. FDA-authorised prescription products exist for defined breast-cancer indications; WADA prohibits aromatase inhibitors at all times. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions.
Unknowns	Insufficient data in the current dataset	Insufficient data in the current dataset	Insufficient data in the current dataset
Limitations	Letrozole molecule or active moiety ≠ ester/salt ≠ formulation ≠ brand ≠ supplier product; biological plausibility or historical use ≠ current approval ≠ safe performance use	Anastrozole molecule or active moiety ≠ ester/salt ≠ formulation ≠ brand ≠ supplier product; biological plausibility or historical use ≠ current approval ≠ safe performance use	Exemestane molecule or active moiety ≠ ester/salt ≠ formulation ≠ brand ≠ supplier product; biological plausibility or historical use ≠ current approval ≠ safe performance use
Sources	DailyMed · Letrozole human drug-label inventory FDA · Why unapproved drugs require product-specific review WADA · 2026 Prohibited List	DailyMed · Anastrozole human drug-label inventory FDA · Why unapproved drugs require product-specific review WADA · 2026 Prohibited List	DailyMed · Exemestane human drug-label inventory FDA · Why unapproved drugs require product-specific review WADA · 2026 Prohibited List
Read more	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)

This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.

Choose another comparison

Continue reading

Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.

10 questions before drawing conclusions

Compare evidence.Keep the context.

Continue reading

Contact PrimeCoreBio

Compare evidence.
Keep the context.